• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices

    Simply Stimulating: Examining the Neurostimulation Sector

    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Tissium's COAPTIUM Connect Achieves Successful Nerve Repair in Australia

    ABB Robots Automate COVID-19 Neutralizing Antibody Test

    Sensydia Achieves Study Target for Heart-Sound AI

    Teleflex to Expand Facility in Jaffrey, New Hampshire

    TransMed7's Concorde Soft Tissue Biopsy Devices Used in First Clinical Cases
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    The Changing Face of Medtech Surface Treatment

    The Totally Tubular Technologies that Support Medical Devices

    Simply Stimulating: Examining the Neurostimulation Sector

    Sensing Technology Drives the Future of Medical Care

    New and Developing Diabetes Technologies Offer 'Sweet Relief'
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Timeline Mystery for Updated EtO Rules

    An Update on Hospital Trends Post-Pandemic

    Don’t Fear the Audit: Benefits of Good Quality Practices

    Understanding the FDA’s Standards & Conformity Assessment Program

    Medtech Divestitures Are Good for Medtech Innovation
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Halkey-Roberts Corporation

    NDH Medical Inc.

    Providence Enterprise USA Inc.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Designing for Manufacturing: 5 Common Startup Mistakes (and How to Avoid Them)

    5 Challenges Medtech Must Address to Transform Healthcare

    3D Printing Medical Devices Revolutionized Manufacturing

    5 Current Trends in Medical Device Security

    How Advanced Sensors Improve Design & Functionality of Respiratory Care Equipment
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Halkey-Roberts Corporation

    NDH Medical Inc.

    Providence Enterprise USA Inc.

    Arthur G. Russell Co. Inc., The

    Cirtec Medical
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Manufacturing’s Great Opportunity

    ...

    Manufacturing’s Great Opportunity
    Bryan Hughes, Director, P&M Corporate Finance03.14.18
    Twelve months ago, Johnson & Johnson subsidiary Ethicon Inc. announced plans to close a surgical suture plant in Livingston, Scotland, and transfer production to facilities in Texas, Mexico, and Brazil. The closure—Ethicon’s second of a Scottish suture manufacturing plant—is part of a global restructuring plan for J&J’s medical device business.

    Announced in early 2016, the plan is designed to accelerate the pace of innovation, address unmet needs, and drive growth. By identifying $1 billion in pretax cost-savings, J&J management anticipates having significantly more resources and flexibility to fund the development of innovative patient solutions. Gary Pruden, Worldwide Chairman of Johnson & Johnson Medical Devices, stated, “The bold steps we are taking are to evolve our offerings, structure, and footprint, and increase our investment in innovation.”

    While $1 billion represents less than 10 percent of the combined cost of goods sold and SG&A of Johnson & Johnson’s device business, the scale of the restructuring effort is significant. The company expects its restructuring effort to cost between $2 billion and $2.4 billion. As importantly, through the end of 2017 J&J had spent almost $1 billion on outside consultants and other project management expenses related specifically to this effort. 

    Prior MPO articles and MPO Summit presentations have explored similar restructuring efforts at Medtronic plc to achieve operating margin improvements of roughly 650 basis points. In that instance, Medtronic used the Covidien synergies as the “catalyst for a long tail of leverage opportunities beyond FY18.” Including an initial $850 million in synergies expected from the Covidien acquisition, Medtronic expects to cut SG&A expenses by $1.7 billion and COGS (cost of goods sold) by more than $3 billion. If J&J follows a similar playbook to Medtronic, more transformative changes will occur as the company reshapes its business.

    Impact From Tax Reform
    These initiatives come as medical device and life sciences companies are critically assessing global supply chain strategies in the wake of the Tax Cuts & Jobs Act and the Trump administration’s decidedly “America First” trade agenda. On one hand, companies like J&J and Medtronic, along with other medical device and pharmaceutical companies, hold tens of billions of dollars in cash outside the United States. Under the new “repatriation tax” rules included in the Tax Cuts & Jobs Act, large companies will have to pay a tax on cash stockpiles whether or not they bring the money back to the United States. Accordingly, many medical device companies absorbed significant one-time earnings charges in Q1 2018 to account for the tax but now have full access to this cash. The ability to access this capital gives companies more flexibility in allocating resources for potential mergers and acquisitions, dividends, and shareholder buybacks. While most CEOs and finance chiefs have suggested the new tax law won’t change capital allocation strategies, they also have hailed the reform package as a boon for M&A.

    In last month’s Dollars & $ense column, Mark Bonifacio highlighted the potential negative impact of tax reform, specifically noting Section 4303’s effect on international supply chains. In typical Washington fashion, Section 4303 was replaced in the final bill with a slightly different U.S. Senate proposal codified in section 59A. The “base erosion and anti-abuse tax” (BEAT) is focused on large corporations and operates differently than Section 4303; for companies with more than $500 million in annual revenue, BEAT is generally calculated as 10 percent of modified taxable income. An explanation of the formula for calculating modified taxable income would take up the balance of this magazine, but suffice to say it functions much like an alternative minimum tax intended to prevent offshoring of income to tax havens. Local profits on medical products manufactured by international subsidiaries may still end up being taxed, but the negative impact on regions like Puerto Rico should be muted. Moreover, in aggregate, the lower corporate tax rates now in place should drive further investment in R&D, new manufacturing facilities, and human capital. These investments, in turn, could fuel future M&A.

    Medical Manufacturing’s Great Opportunity
    Market forces within healthcare are rapidly changing. To be successful and drive shareholder value in a low-tax environment, medical technology companies must continuously invest in innovation. One such strategy employed by OEMs like J&J entails spending hundreds of millions of dollars annually with outside consultants on restructuring and/or business reinvigoration plans. As global consulting firms like McKinsey, Bain, and The Boston Consulting Group (BCG) develop deep institutional knowledge on industry best practices, this insight often filters back to the broader public via white papers and other thought pieces. 

    In December, BCG released one such publication titled, “Medtech Manufacturing’s Inflection Point.”  Focused on discussing that firm’s recent analysis of the medical manufacturing landscape, as well as executive interviews regarding manufacturing strategy, the report could be viewed as a rallying cry to transform medical product manufacturing. The report begins by observing that medical technology manufacturing networks have grown bigger over the last decade, but they have not necessarily improved.

    Among other data points supporting this observation, the BCG team analyzed a comprehensive database of U.S. Food and Drug Administration (FDA) registration filings over the last eight years and concluded:

    • Medtech supply chains are not optimized to take advantage of scale benefits
    • The complexity and diversity of medtech portfolios creates a manufacturing challenge
    • Medtech lags other industries in shifting production to low-cost countries
    • Despite the prior points, contract manufacturing has increased

    It’s unclear whether this analysis considered the impact of 2012 changes to FDA regulations on device establishment registration; however, the conclusion about the percentage of currently outsourced device manufacturing aligns closely with PMCF’s own analysis. While we view each of these findings as important to understanding the constantly changing landscape within medical product outsourcing, I view the specific conclusions around contract manufacturing as most interesting. In part, this is because BCG’s observations overlay with many of the considerations we have discussed previously:

    • Enhanced capabilities across suppliers
    • Impact of consolidation on capabilities and scale
    • Aggressive pursuit of medtech by traditional EMS/interconnect firms

    More importantly, the authors of this whitepaper and their peers at other firms are presumably very active voices in C-suite and board level discussions regarding manufacturing strategy at the largest players in medtech. It is hard to believe they would make strong statements in this forum, and yet advise their clients to “keep doing what they’re doing.”

    Assuming this is indeed true, the industry likely is in for a very interesting ride over the next several years as the supply chain transforms itself. BCG concluded its assessment by stating, “It’s time for medtech companies to become more proactive and systematic about building the manufacturing network they need to thrive in a more dynamic and competitive market.”

    So Now What?
    From a practical perspective, what does that statement really mean for the medical product outsourcing industry? And for that matter, will the drastically changed tax landscape have an impact on where products and devices are manufactured? What will J&J’s restructured Medical Device business and supply chain look like? At last year’s MPO Summit, Randall Sword and I concluded our presentation by presenting four key takeaways and asking three critical questions.  In the context of the aforementioned BCG publication, it seems wise to re-examine these points.

    • OEM consolidation and pricing pressure. The healthcare industry is currently experiencing fundamental change. In the face of this change, and parallel price pressure, medical device OEMs are evolving and seeking operational and R&D leverage through acquisition. This will place downward pressure on manufacturing networks as footprints are integrated and companies seek maximum operational leverage to reinvest capital in innovative new technologies.
    • Fragmentation, yet differentiation. The Top 20 medical contract manufacturers (CMs) generate approximately $12 billion in annual revenue. As customers consolidate and focus more resources on the supply chain, the largest CMs will respond by getting larger themselves. This growing list of large suppliers provides device OEMs advantages from scale, flexibility in geographic sourcing, and dedicated capabilities that may not otherwise exist in house.
    • What happens to innovation? Device companies may need to increase their focus on portfolio management and optimization in order to dedicate resources to developing innovative technologies. Accordingly, there likely will be further divestitures of slower growth product lines/portfolios. In the near-term, product lifecycle management may be reimagined with legacy, slow growth products potentially “outsourced” to supply chain partners responsible for the full continuum of manufacturing, and product-line extensions and related development.  
    • Will medtech become merely an end market? Companies like Nordson, SFS Group, and TE Connectivity have grown their medical franchises quickly through acquisition, and yet medical still represents a small percentage of their overall revenue. With EMS players like Flex, Jabil, and Celestica also aggressively pursuing medtech, expect medical products and devices to become a much larger percentage of industrial conglomerates’ revenue. As these players seek further scale, it is likely they will benefit from larger program awards, and drive M&A activity.
    • If margins suffer, what happens to quality? Quality is table stakes in this industry. While there will always be pressure on margins, the quality requirements as demanded by OEMs, dictated by the FDA, and essential for patients cannot be softened. Accordingly, suppliers facing margin pressure may need to invest in automation or other continuous improvement initiatives to maintain the financial return necessary to sustain quality. Those that can’t stay in the market long, won’t remain, perhaps further accelerating supplier consolidation.
    • As much as this industry is focused on innovative devices and solutions, change tends to come slowly.  Perhaps the corporate restructuring currently underway at Medtronic, J&J, and others represents the inflection point in medtech manufacturing.  As an industry, hopefully OEMs and suppliers will seize the opportunity and radically rethink manufacturing networks. Will this lead to focused outsourcing, more lifecycle partnering, and robust M&A activity? Only time will tell. 


    Bryan Hughes is a director of PMCF and leads the firm’s medical technology team. His practice focuses on assisting medical technology and medical manufacturing clients with mergers and acquisitions, leveraged buyouts, private placements, financings, valuation and strategic consulting. His clients have ranged from global medical technology companies to small, privately held businesses.
    Related Searches
    • medical device
    • first
    • medtech
    • trump
    Suggested For You
    MEDICAL & BIOTECH MANUFACTURING MEDICAL & BIOTECH MANUFACTURING
    MedWorld Advisors MedWorld Advisors
    Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles
    Accu-Tube Appoints Matthew Haddle as CEO Accu-Tube Appoints Matthew Haddle as CEO
    Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings
    CE Mark Granted to Predictive Software for Kidney Allograft Survival CE Mark Granted to Predictive Software for Kidney Allograft Survival
    Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech Electroducer Raises 3 Million Euros to Market Heart Valve Disease Tech
    Precision Coating Merges with N2 Biomedical Precision Coating Merges with N2 Biomedical
    Presidio Medical Names Michael Onuscheck as CEO Presidio Medical Names Michael Onuscheck as CEO
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Indago Announces $10 Million Financing Close and Name Change Indago Announces $10 Million Financing Close and Name Change
    Molli Surgical Molli Surgical's Breast Tumor Marker
    Vertigo Treatment Receives FDA Breakthrough Device Designation Vertigo Treatment Receives FDA Breakthrough Device Designation
    RapidPulse Closes $15 Million Series A Financing RapidPulse Closes $15 Million Series A Financing
    Midwest Products & Engineering Acquires MindFlow Design Midwest Products & Engineering Acquires MindFlow Design

    Related Literature / Brochures

    • MEDICAL & BIOTECH MANUFACTURING

      ISO 13485:2016 • FDA Registered

    • MedWorld Advisors

      MedWorld Advisors

      ...
      Florence Joffroy-Black, CEO/President 11.29.22

    • Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Hyperfine Names Paykel, Teisseyre to Executive Leadership Roles

      Neela Paykel is serving as general counsel and Tom Teisseyre assumes the chief product officer position.
      Business Wire 09.22.21


    • Tubing & Extrusion
      Accu-Tube Appoints Matthew Haddle as CEO

      Accu-Tube Appoints Matthew Haddle as CEO

      Haddle has a track record of leading organizations through strategic expansions across the medical device, aerospace, and industrial sectors.
      Accu-Tube 09.22.21

    • Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      Heraeus Acquires Mo-Sci Corporation, ETS Technology Holdings

      The two deals will strengthen Heraeus' healthcare and medtech portfolio.
      Heraeus 09.22.21

    Loading, Please Wait..

    Breaking News
    • Tissium's COAPTIUM Connect Achieves Successful Nerve Repair in Australia
    • ABB Robots Automate COVID-19 Neutralizing Antibody Test
    • Sensydia Achieves Study Target for Heart-Sound AI
    • Canadian Health System Evaluating Abdominal Wound Closure Tech
    • Teleflex to Expand Facility in Jaffrey, New Hampshire
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Sensing Technology Drives the Future of Medical Care
    • New and Developing Diabetes Technologies Offer 'Sweet Relief'
    • Discussing Matters of Substance in Medtech Materials
    • Medical Device Testers Are Caught Up in a Whirlwind
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Jiaherb Receives CITES Certification for Rhodiola Rosea
    Hyaluronic Acid Ingredient Linked to Antioxidant Benefits In Vitro
    Anita Johansen Appointed New CEO of Probi
    Coatings World

    Latest Breaking News From Coatings World

    BASF’s Monomers Division Receive ISCC+ Certification in Its Two Asian Production Sites
    Omya to Represent Songwon’s Coatings Portfolio in 4 South-Asian Countries
    Brenntag Commences Operations at Its New Site in Zhangjiagang, China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Tissium's COAPTIUM Connect Achieves Successful Nerve Repair in Australia
    ABB Robots Automate COVID-19 Neutralizing Antibody Test
    Sensydia Achieves Study Target for Heart-Sound AI
    Contract Pharma

    Latest Breaking News From Contract Pharma

    GSK, Scynexis Partner to Develop Brexafemme for Drug-Resistant Fungal Infections
    Mytide Names Martina Diekmann CEO
    Quotient Sciences Supports Crinetics Pharma with Pediatric Development, Clinical Testing Program
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Venus Launches Dermaplaning Skincare Regimen
    Olberding Brand Family Updates Leadership Team and Expands Capabilities
    Rimmel London Chooses Maya Jama as the New Face of the Brand
    Happi

    Latest Breaking News From Happi

    Pura Collaborates with the Metropolitan Museum of Art on New Fragrance Collection
    Erin Keating is Newest C-Suite Hire at Maesa
    Coty Appoints Caroline Andreotti as Chief Commercial Officer, Prestige
    Ink World

    Latest Breaking News From Ink World

    ACTEGA to Showcase Products and Solutions at Interpack 2023
    hubergroup Print Solutions Takes Stock of Digital Print Folders
    INX International Makes Investment in Gooten
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    CUPSZ chooses Mark Andy Evolution Series E5
    Registration opens for RadTech Europe webinar series
    Beontag moves up on list of Fastest Growing Companies 2023
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Binder Unveils New Look, Website
    Drylock Technologies Plants First Trees in Drylock Forest
    A.Celli Group to Hold Open House
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    European Innovation Council Awards Grant for Brain-Computer Interface Tech
    Report: No Complications With OssDsign Catalyst Graft
    FDA OKs Bioretec's RemeOs Bioresorbable Metal Trauma Screw
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Emerson Named 2023 ENERGY STAR Partner of the Year
    Nano Dimension Increases Offer to Acquire Stratasys to $19.55 Per Share in Cash
    Universal Display Sponsors, Presents at ICDT 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login